Semaglutide is currently FDA-approved for chronic weight management under the brand name Wegovy, with efficacy data from the STEP clinical trials supporting its use in adults with obesity or overweight with related comorbidities
Treatment is HSA/FSA eligible and available in all 50 states without insurance
They skip the side effects, the plateau weeks, the dosage changes, and the crucial question nobody asks out loud: what happens after six weeks when the easy results slow down
You dont need to become an athlete
Many New Jersey patients choose medical weight loss after struggling with traditional diets or inconsistent results
- Evidence: Meta-analysis: 91 placebo-controlled trials, 107,910 patients Retrospective cohort study: 2.2M users via FDA Sentinel System No signal for SI/B, anxiety, depression, irritability, or psychosis - Action: FDA requesting removal of SI/B warning from Wegovy, Saxenda, and Zepbound labeling